Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 21, 2015

Key Late-breaking Trials to Watch at ACC.15

The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in March. Here are my top picks for cardiovascular device technology I am looking forward to hearing data on: 

1. Perhaps the key trial at ACC will be data from the large BEST study, which compares the Xience V drug-eluting stent (DES) to coronary bypass grft (CABG) surgery in patients with multivessel disease. It is a follow up to the SYNTAX trial, which fell short in showing the Taxus DES (at the time the top-performing stent) had long-term durability compared to CABG. However, Abbott's Xience second-generation DES beat out Taxus in the SPRIRT IV trial a couple years ago. Intervascular imaging and FFR today also see more expanded use, which combined with an improved stent platform, is expected to tip the scale in favor of stenting. 

2. More data will be presented, likely further supporting the use of transcatheter aortic valve replacement (TAVR). This includes long-term outcomes from the Edwards Sapien and Medtronic Corevalve trials, and first experience with use of a TAVR embolic protection system. The most important of the trial presentations might be data from an all-comers trial of TAVR verses surgery. This data could help open the flood gates for TAVR as a standard therapy to replace open heart procedures.
 
3. Use of CT angiography to evaluate patients presenting with chest pain to reduce costs. There a a few CTA trials being presented, which I suspect will add more evidence that CTA can be used as a primary rule-out test to help eliminate series blood testing, nuclear scans, stress tests and diagnostic angiograms.
 
4. Denervation to treat pulmonary hypertension. Renal denervation trials have had very mixed results, but experts still say the denervation may hold promise for other therapeutic areas such as this one.
 
5. Initial experience and outcomes with the MitraClip mital valve leaflet repair system. I believe this is just the beginning of a whole new segment of interventional mitral valve repair therapies that will eventually replace open heart mitral procedures.
 
6. There are two trials comparing transradial access, which is a growing trend in the United States to help lower access site complications. One will compare transradial to transfemoral access sites, and another radial verses ulnar access. 
 
See the complete list of late breaking trials, presentation locations and times. 

Below is a preview of some technologies being shown on the expo floor.

 

Related Content

Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

News | Heart Failure | April 26, 2021
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States.
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating
Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

News | Heart Failure | March 03, 2021
March 3, 2021 — Impulse Dynamics recently announced that...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — P...
The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.
News | Heart Failure | February 24, 2021
February 24, 2021 — Occlutech announced the completion of patient enrollment in the PRELIEVE trial, pilot study to as
The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.

The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.
 

News | Heart Failure | January 27, 2021
January, 27, 2021 — The U.S.
FDA clears Verquvo, Vericiguat, Heart failure drug.
News | Heart Failure | January 25, 2021
January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat).
The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

News | Heart Failure | January 13, 2021
January 13, 2021 — FineHeart, a preclinical-stage medical device company developing a novel...
HeartMate 3 heart pump is now approved for use for pediatric patients battling advanced heart failure offering a new treatment option for this underserved population
News | Heart Failure | December 21, 2020
December 21, 2020 — U.S.
CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure | December 02, 2020
December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage polici